Farnesyltransferase Inhibitors and Their Role in the Treatment of Multiple Myeloma

Cancer Control

Volumn 10, Issue 5, 2003, Pages 384-387

  Santucci, Rodrigo ^b   Mackley, Paul A ^a   Sebti, Saïd ^a   Alsina, Melissa ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b FACULDADE DE MEDICINA DO ABC   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 214664; DOXORUBICIN; GERANYLGERANYLTRANSFERASE I INHIBITOR; GGTI 2166; L 778123; MELPHALAN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROPIDIUM IODIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; SCH 66363; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HUMAN; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; ONCOGENE; PROTEIN PROCESSING; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0142054025     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480301000505     Document Type: Review

References (41)

1. Anderson KC. Targeting myeloma cell-host bone marrow interactions. American Society of Clinical Oncology 2002 Education Book. 2002:79-486.
2. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
3. Shain KH, Dalton WS. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther. 2001;1:69-78.
4. Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood. 2000;96:1953-1960.
5. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159:2212-2221.
6. Hideshima T, Nakamura N, Chauhan D, et al. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991-6000.
7. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway. Eur J Immunol. 1999;29:3945-3950.
8. Corradini P, Ladetto M,Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81:2708-2713.
9. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93:1062-1074.
10. Dancey JE. Agents targeting ras signaling pathway. Curr Pharm Des. 2002;8:2259-2267.
11. Sebti S, Hamilton AD. Inhibitors of prenyl transferases. Curr Opin Oncol. 1997;9:557-561.
12. Kohl NE. Farnesyltransferase inhibitors: preclinical development. Ann N Y Acad Sci. 1999;886:91-102.
13. Feldkamp MM, Lau N, Roncari L, et al. Isotype-specific Ras GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 2001;61:4425-4431.
14. Shi Y, Gera J, Hsu JH, et al. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells. Mol Cancer Ther. 2003;2:563-572.
15. Lobell RB, Omer CA, Abrams MT, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitors combinations in preclinical models. Cancer Res. 2001;61:8758-8768.
16. Kamasani U, Liu AX, Prendergast GC. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther. 2003;2:273-280.
17. Lieberman R, Bermejo C, Akaza H, et al. Progress in prostate cancer chemoprevention: modulators of promotion and progression. Urology. 2001;58:835-842.
18. Jones HA, Hahn SM, Bernhard E, et al. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001;11:328-337.
19. Johnston SR, Kelland LR. Farnesyl transferase inhibitors: a novel therapy for breast cancer. EndocrRelat Cancer. 2001;8:227-235
20. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase I setting. Blood. 2003. In press.
21. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood. 2001;97:3361-3369
22. Barbacid M. Ras genes. Annu Rev Biochem. 1987;56:779-827.
23. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-269.
24. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996;88:2699-2706.
25. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001;18:212-224.
26. Kalakonda N, Rothwell DG, Scarffe JH, et al. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood. 2001;8:1555-1560.
27. Venet M, End D, Angibaud P. Farnesyl protein transferase inhibitor ZARNESTRA R115777: history of a discovery. Curr Top Med Chem. 2003;3:1095-1102.
28. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
29. Smith V, Rowlands MG, Barrie E, et al. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res. 2002;8:2002-2009.
30. Dempke WC. Farnesyltransferase inhibitors: a novel approach in the treatment of advanced pancreatic carcinomas. Anticancer Res. 2003;23:813-818.
31. Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2002;20:2726-2735.
32. Adjei AA, Croghan GA, Erlichman C, et al. A phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003;9:2520-2526.
33. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003;21:2492-2499.
34. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:1760-1766.
35. Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003;21:1301-1306.
36. Bolick SC, Landowski TH, Boulware D, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 2003;17:451-457.
37. Ochiai N, Uchida R, Fuchida SI, et al. Effect of farnesyl transferase inhibitor R115777 (Zarnestra) on the growth of fresh and cloned myeloma cells in vitro. Blood. 2003:July 3. Epub ahead of print.
38. Mackley PA, Shain KH, Dalton WS, et al. Farnesyl transferase inhibitor R115777 decreases Akt phosphorylation in multiple myeloma cell lines and its apoptotic effects correlate with phosphoAKT expression levels. Blood. 2002:3198. Abstract.
39. Alsina M, Fonseca R, Wilson EF, et al. The farnesyl transferase inhibitor Zarnestra is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2003. Submitted.
40. Salmon SE, Crowley JJ, Grogan TM, et al. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol. 1994;12:2405-2414.
41. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000;20:139-148.